Human Neutralizing Monoclonal Antibodies to Respiratory Syncytial Virus and Human Neutralizing Antibodies to Respiratory Syncytial Virus


This invention is a human monoclonal antibody fragment (Fab) discovered utilizing phage display technology. It is described in Crowe et al., Proc Natl Acad Sci USA. 1994 Feb 15;91(4):1386-1390 (PubMed abs) and Barbas et al., Proc Natl Acad Sci USA. 1992 Nov 1;89(21):10164-10168 (PubMed abs). This MAb binds an epitope on the RSV F glycoprotein at amino acid 266 with an affinity of approximately 109M-1. This MAb neutralized each of 10 subgroup A and 9 subgroup B RSV strains with high efficiency. It was effective in reducing the amount of RSV in lungs of RSV-infected cotton rats 24 hours after treatment, and successive treatments caused an even greater reduction in the amount of RSV detected.

Potential Commercial Applications: Competitive Advantages:
Research and drug development for treatment of respiratory syncytial virus 


Inventors:

Robert Chanock (NIAID)  ➽ more inventions...

James Crowe (NIAID)  ➽ more inventions...

Brian Murphy (NIAID)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 6,685,942 issued 2004-02-03
U.S. Pat: 5,762,905 issued 1998-06-09
US Application No. 08/162,102

Licensing Contact:
Peter Soukas, J.D.
Email: peter.soukas@nih.gov
Phone: 301-496-2644

OTT Reference No: E-032-1993-1
Updated: Sep 1, 2008